336 related articles for article (PubMed ID: 9527161)
1. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis.
Lycke JN; Karlsson JE; Andersen O; Rosengren LE
J Neurol Neurosurg Psychiatry; 1998 Mar; 64(3):402-4. PubMed ID: 9527161
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis.
Villar LM; Picón C; Costa-Frossard L; Alenda R; García-Caldentey J; Espiño M; Muriel A; Álvarez-Cermeño JC
Eur J Neurol; 2015 Aug; 22(8):1169-75. PubMed ID: 25324032
[TBL] [Abstract][Full Text] [Related]
3. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies.
Martin SJ; McGlasson S; Hunt D; Overell J
J Neurol Neurosurg Psychiatry; 2019 Sep; 90(9):1059-1067. PubMed ID: 31123141
[TBL] [Abstract][Full Text] [Related]
5. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J
Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D and axonal injury in multiple sclerosis.
Sandberg L; Biström M; Salzer J; Vågberg M; Svenningsson A; Sundström P
Mult Scler; 2016 Jul; 22(8):1027-31. PubMed ID: 26462862
[TBL] [Abstract][Full Text] [Related]
7. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability.
Semra YK; Seidi OA; Sharief MK
J Neuroimmunol; 2002 Jan; 122(1-2):132-9. PubMed ID: 11777552
[TBL] [Abstract][Full Text] [Related]
8. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis.
Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
Eur J Neurol; 2017 May; 24(5):703-712. PubMed ID: 28261960
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of CSF neurofilament light and heavy chain protein in MS.
Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L
Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999
[TBL] [Abstract][Full Text] [Related]
10. Neurofilament light chain as an indicator of exacerbation prior to clinical symptoms in multiple sclerosis.
Edwards KR; Garten L; Button J; O'Connor J; Kamath V; Frazier C
Mult Scler Relat Disord; 2019 Jun; 31():59-61. PubMed ID: 30927733
[TBL] [Abstract][Full Text] [Related]
11. High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome.
van der Vuurst de Vries RM; Wong YYM; Mescheriakova JY; van Pelt ED; Runia TF; Jafari N; Siepman TA; Melief MJ; Wierenga-Wolf AF; van Luijn MM; Samijn JP; Neuteboom RF; Hintzen RQ
Mult Scler; 2019 Jun; 25(7):958-967. PubMed ID: 29774770
[TBL] [Abstract][Full Text] [Related]
12. Neurofilaments and 10-year follow-up in multiple sclerosis.
Bhan A; Jacobsen C; Myhr KM; Dalen I; Lode K; Farbu E
Mult Scler; 2018 Sep; 24(10):1301-1307. PubMed ID: 30066611
[TBL] [Abstract][Full Text] [Related]
13. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.
Novakova L; Zetterberg H; Sundström P; Axelsson M; Khademi M; Gunnarsson M; Malmeström C; Svenningsson A; Olsson T; Piehl F; Blennow K; Lycke J
Neurology; 2017 Nov; 89(22):2230-2237. PubMed ID: 29079686
[TBL] [Abstract][Full Text] [Related]
14. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis.
Gaetani L; Salvadori N; Lisetti V; Eusebi P; Mancini A; Gentili L; Borrelli A; Portaccio E; Sarchielli P; Blennow K; Zetterberg H; Parnetti L; Calabresi P; Di Filippo M
J Neurol; 2019 Sep; 266(9):2157-2163. PubMed ID: 31129709
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression.
Albanese M; Zagaglia S; Landi D; Boffa L; Nicoletti CG; Marciani MG; Mandolesi G; Marfia GA; Buttari F; Mori F; Centonze D
J Neuroinflammation; 2016 Feb; 13():36. PubMed ID: 26863878
[TBL] [Abstract][Full Text] [Related]
17. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
[TBL] [Abstract][Full Text] [Related]
18. Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease.
Peng L; Bi C; Xia D; Mao L; Qian H
Mult Scler Relat Disord; 2019 May; 30():123-128. PubMed ID: 30771578
[TBL] [Abstract][Full Text] [Related]
19. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis.
Fialová L; Bartos A; Svarcová J; Zimova D; Kotoucova J; Malbohan I
J Neuroimmunol; 2013 Sep; 262(1-2):113-20. PubMed ID: 23870535
[TBL] [Abstract][Full Text] [Related]
20. Neurofilament light chain in the assessment of patients with multiple sclerosis.
Domingues RB; Fernandes GBP; Leite FBVM; Senne C
Arq Neuropsiquiatr; 2019 Jul; 77(6):436-441. PubMed ID: 31314847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
